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The effectiveness of medical nutritiontherapy (MNT) in the managementof diabetes has been well established
(1). Previous reviews have provided com-
prehensive recommendations for MNT in
the management of diabetes (2,3). The
goals of MNT are to 1) attain andmaintain
optimal blood glucose levels, a lipid and
lipoprotein profile that reduces the risk of
macrovascular disease, and blood pres-
sure levels that reduce the risk for vascular
disease; 2) prevent and treat the chronic
complications of diabetes by modifying
nutrient intake and lifestyle; 3) address
individual nutrition needs, taking into ac-
count personal and cultural preferences
and willingness to change; and 4) main-
tain the pleasure of eating by only limiting
food choices when indicated by scientific
evidence (4).
The literature on nutrition as it relates
to diabetes management is vast. We un-
dertook the specific topic of the role of
macronutrients, eating patterns, and in-
dividual foods in response to continued
controversy over independent contribu-
tions of specific foods and macronu-
trients, independent of weight loss, in
the management of diabetes. The position
of the American Diabetes Association
(ADA) on MNT is that each person with
diabetes should receive an individual-
ized eating plan (4). ADA has received
numerous criticisms because it does
not recommend one specific mix of
macronutrients for everyone with diabe-
tes. The previous literature review con-
ducted by ADA in 2001 supported the
idea that there was not one ideal macro-
nutrient distribution for all people with
diabetes. This review focuses on literature
that has been published since that 2001
date (5). This systematic review will be
one source of information considered
when updating the current ADANutrition
Position Statement (4). Other systematic
reviews and key research studies that
may not be included in this review will
also be considered.
When attempting to tease out the role
of macronutrients from other dietary and
lifestyle factors, two critical components
of MNTdenergy balance and a healthful
eating patterndare not addressed. While
both are critical components in the man-
agement of diabetes as well as the second-
ary prevention of complications and
promotion of health, these topics are be-
yond the scope of this particular review.
The following questions are addressed in
this review:
1. What aspects ofmacronutrient quantity
and quality impact glycemic control
and cardiovascular disease (CVD) risk
in people with diabetes?
2. How do macronutrients combine
in whole foods and eating patterns
to affect health in people with dia-
betes?
3. Is there an optimal macronutrient
ratio for glycemic management and
CVD risk reduction in people with
diabetes?
4. What findings and needs should direct
future research?
Systematic review
proceduredA search of the PubMed
database was conducted using the search
terms “diabetes” and one of a number of
words (low-fat diet, low-carbohydrate
diet, Mediterranean diet, Mediterranean
eating pattern, vegetarian, vegan, glyce-
mic index (GI), dietary carbohydrates, di-
etary protein, total fat, dietary fat,
saturated fat, omega-3 fatty acid, dietary
fiber, meats, legumes, nuts, fruit, vegeta-
bles, whole grains, milk) to identify arti-
cles published between January 2001 and
October 2010. Certain terms relevant to
nutrition therapy in the management of
diabetes were not included in the search
terms. These terms include trans fatty
acids, monounsaturated fatty acids (MU-
FAs), polyunsaturated fatty acids (PU-
FAs), sucrose, and sugars. The literature
search was limited to articles published in
English, and multiple publications from
the same study were limited to the pri-
mary study results article.
Studies included in the systematic
review were conducted in people already
diagnosed with diabetes; conducted in
outpatient ambulatory care settings;
contained a sample size of 10 or more
participants in each study group; and one
of the following study designs: clinical
trials (controlled and randomized con-
trolled [RCT]), prospective observational
studies, cross-sectional observational stud-
ies, or case-control studies. Studies were
excluded if they were published before
January 2001 or after October 2010; were
conducted in acute care or inpatient set-
tings, in women with gestational diabetes,
children under 2 years of age, or individ-
uals without diabetes or at risk for diabetes;
had less than 10 participants in any study
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group;were studies lasting only 1 or 2 days;
or were not in one of the study designs
previously listed.
In an effort to expand the research
review, studies were not excluded based
on retention rates; however, this infor-
mation is included in Supplementary Ta-
ble 1 and only studies with a retention
rate of .80% are included in the key
summary for each topic area. Weight
loss is a confounder in some of the studies
and is noted in Supplementary Table 1.
Meta-analyses published during the in-
clusionperiod of this systematic reviewwere
reviewed for studies meeting this systematic
review’s criteria. This information can be
found in Supplementary Table 1.
An initial PubMed database search
found 152 studies after excluding by title
and abstract review. An additional 18
studies were found from bibliography re-
view. Of these, 72 studies were excluded for
not meeting inclusion criteria. The most
common reasons for exclusion were for
results not applicable to the research ques-
tion, not published in amajor journal, small




the effects of dietary macronutrient com-
position on glycemic control and CVD risk
is difficult due to confounding, especially
by weight loss and medication changes.
Furthermore, altering the level of one
macronutrient affects the proportion of
other macronutrients, making it difficult
to isolate the true exposure. Additional
study design issues include the difficulty
blinding study participants, investigators,
and clinicians. Finally, the lack of stan-
dardized definitions for terms such as “low-
fat (or high-fat) diet,” “low-carbohydrate
(or high-carbohydrate) diet,” and “low-
GI (or high-GI) diet” makes comparisons
among study results difficult. These is-
sues were addressed by reporting the en-
tire macronutrient composition of diet
approaches and potential confounders
when this information was available.
Question 1: What aspects of
macronutrient quantity and
quality impact glycemic
control and CVD risk in
people with diabetes?
Carbohydrate amountdThere is
no consistent definition of “low- (or
high-) carbohydrate diets” throughout
the literature. Based on the studies in this
systematic review, the following defini-
tions are used:
c very-low-carbohydrate diet: 21–70 g/day
of carbohydrate
c moderately low–carbohydrate diet: 30
to ,40% of kcal as carbohydrate
c moderate-carbohydrate diet: 40–65%
of kcal as carbohydrate
c high-carbohydrate diet: .65% of kcal
as carbohydrate
These definitions are not all-inclusive
(e.g., a 100-g/day carbohydrate diet may
be ,30% kcal), but they represent the
typical definitions used by authors, and
all published articles fit in one of these
categories.
Many studies use the term “conven-
tional” or “traditional”macronutrient dis-
tribution as a comparison group. Based
on studies in this review, these terms refer
to an energy contribution from the diet of
55–65% carbohydrate, #30% fat, and
10–20% protein. It should be noted that
people with diabetes have been shown to
consume an eating pattern that is about
45% of calories from carbohydrate (6–9).
The comparison diets referred to as con-
ventional or traditional throughout this
review are higher in carbohydrate than
those generally consumed by people
with diabetes.
Lower (very low and moderately low)
carbohydrate
Glycemic control. Eleven clinical trials
examined the effects of lowering total
carbohydrate intake on glycemic control
in individuals with diabetes. The carbo-
hydrate content goal of the diet was very
low in 7 studies (10–16) and moderately
low in 4 studies (17–20).
All studies included adults with type
2 diabetes, duration of follow-up ranged
from 14 days to 1 year, and sample sizes
ranged from 10 to 55 participants per
study group. Designs included two feed-
ing trials (one crossover clinical trial and
one RCT) (10,18) and nine outpatient
nutrition counseling interventions (two
single-arm clinical trials, one crossover
RCT, and six parallel RCTs) (11–17,19,20).
All studies analyzed participants according
to treatment assignment, eight studies were
randomized (11–13,15–19), and for six
studies, completion of follow-up was 80%
or higher (10,12,13,17–19).
A1C decreased with a lower-
carbohydrate diet in 6 of 10 studies in
which it was measured (10,14–17,20).
Three RCTs found no statistically signif-
icant changes in A1C with a very-low-
carbohydrate diet (11–13) and one
found no difference with a moderately
low–carbohydrate diet (19). Other gly-
cemic parameters such as fasting blood
glucose (FBG), 24-h blood glucose, 24-h
insulin (10), and fasting insulin levels
(18) decreased significantly, and insulin
sensitivity increased significantly (10)
on the lower-carbohydrate diet. Glucose-
loweringmedicationswere decreased for in-
dividuals following the lower-carbohydrate
diet (10–12,14,17) or were more frequently
decreased than in the comparison diet (16).
CVD risk. Each of the 11 clinical trials
reported at least one serum lipoprotein.
The most notable results were that HDL
cholesterol increased significantly more
in one very-low-carbohydrate diet group
(16) and twomoderately low–carbohydrate
diet groups (18,20) compared with the
higher-carbohydrate control diet. Also, tri-
glycerides (TGs) decreased more in one
moderately low–carbohydrate diet group
(20) comparedwith the higher-carbohydrate
control diet. Otherwise, mean changes in
serum lipoproteins resulting from a lower-
carbohydrate diet were typically beneficial
but occurred without a comparison arm or




In studies reducing total carbohydrate
intake, markers of glycemic control and
insulin sensitivity improved, but studies
were small, of short duration, and in some
cases were not randomized or had high
dropout rates. Serum lipoproteins typi-
cally improved with reduction of total
carbohydrate intake but, with the excep-
tion of HDL cholesterol, were not statis-
tically greater than with the comparison
diet. The contribution of weight loss to
the results was not clear in some of these
studies.
Moderate or high carbohydrate
Glycemic control. Seven clinical trials
and two meta-analyses examined the
effects of moderate- or high-carbohydrate
diets on glycemic control in patients with
type 2 diabetes (21–28) or type 1 diabetes
(29). Durations of follow-up ranged from
5 to 74 weeks, and sample sizes of partic-
ipants completing follow-up ranged from
10 to 99. All seven studies were RCTs
and analyzed participants according to
treatment assignment. Four studies had
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completion of follow-up of 80% or higher
(21,22,25,26). Only one of the studies
blinded participants to diet treatment (22),
and none blinded the outcome assessors.
Four studies found no significant
differences in glycemic controlwhencom-
paring moderate- or high-carbohydrate
diets with conventional diets (21–24).
One RCT found A1C improved with
higher carbohydrate (75% of energy in-
take) compared with conventional carbo-
hydrate (60–70% of energy intake) (21)
in secondary analyses that used the obser-
vation immediately prior to a participant
dropping out or having a diabetes medi-
cation change as the final outcome. The
intent-to-treat analyses, however, showed
no significant differences between groups.
In another study, A1C decreased signif-
icantly more during 5 weeks on a 40%
carbohydrate/30% protein versus a 55%
carbohydrate/15% protein diet (25). A1C
was not significantly different compared
with a conventional diet in two studies
examining a moderate-carbohydrate/
higher-protein diet (23,24), two studies
examining a moderate-carbohydrate/
higher-fat (MUFA) diet (22,26), and one
study comparing a 55% carbohydrate/
25% fat with a 55% carbohydrate/30%
fat diet (29).
Regarding other glycemic parameters,
24-h glucose response was lower with a
40% carbohydrate/30% protein diet
compared with a 55% carbohydrate/
15% protein diet (25); however, plasma
glucose (22–24,26), plasma insulin
(23,24,26,29), plasma fructosamine
(22), and homeostasis model assessment
(HOMA) (24) were not significantly dif-
ferent in other diet comparisons.
Two meta-analyses compared lower-
carbohydrate diets with conventional car-
bohydrate diets (27,28). Of the 19 studies
reviewed in the article byKodama et al. (27),
only three (18,26,30) were published dur-
ing the date range for this review, and of the
13 studies in the meta-analysis by Kirk et al.
(28), only four (10,14,22,25) were pub-
lished during the review time period. The
seven studies are included in this review.
CVD risk. Six of the seven interventions
reviewed above reported lipoproteins.
Two (25,26) reported significant reduc-
tions in TGs on a 40% carbohydrate diet
(vs. 50–55% carbohydrate), whereas one
(21) observed a significant reduction in
LDL cholesterol on a 75% carbohydrate
diet (vs. 60–70% carbohydrate). Three
studies (22–24) found no significant dif-
ferences between comparison diets.
Summary of moderate- and high-
carbohydrate research since 2002
RCTs presenting information onmoderate-
and high-carbohydrate diets are diverse
in terms of fat and protein content as
well as length of study. Only two RCTs
found significant differences in A1C be-
tween groups, with one study finding
significantly lower A1C with the higher-
carbohydrate diet only in a subgroup
analysis, and the other study finding
significantly lower A1C with the lower-
carbohydrate diet. In terms of CVD risk
factors, LDL cholesterol improved more
with a high-carbohydrate diet in one
study, whereas two studies found TGs
improved more with a lower-carbohydrate
diet.
Carbohydrate typedStudies in
this systematic review addressing the
type of carbohydrate were those of GI/
glycemic load or dietary fiber.
GI
For studies in this review that provided
the GI that subjects were able to achieve
(end-of-study GI numbers), there was
no agreement as to the definition of “low
GI” (range 39–77) or “high GI” (range
56–84). The meta-analyses (almost all
studies used were published before
2001) found that the average low GI
was 65, and the average high GI was
82, but both had wide ranges. This is
further complicated by the two bases
(glucose or white bread) that have been
used to determine GI values for individ-
ual foods.
Glycemic control. Five RCTs (19,31–
34) compared lower-GI diets with
higher-GI diets in individuals with type
2 diabetes. Duration of follow-up ranged
from 4 to 6 weeks and sample sizes were
small in four studies (12–14 in three of
the studies, 45 in the other), whereas the
fifth study lasted for 1 year and included
156 subjects in the analysis (19). Comple-
tion rates were $80% except for 39% in
one study (33). Results were mixed with
two studies finding A1C was significantly
reduced with the lower-GI versus higher-
GI diets (32,33) and the others finding
no differences in glycemic measures
(19,31,34).
Three parallel RCTs (16,35,36)
compared a lower-GI diet with diets
other than those designated as higher GI
(high-fiber diet, traditional diet, very-
low-carbohydrate diet) in individuals with
type 2 diabetes. Duration of follow-up was
6–12 months, retention rates were ,80%
in two of the studies (16,35), and sample
sizes were moderate (range 40–155). Com-
pared with a higher-fiber diet, the lower-GI
diet decreased A1C and FBG significantly
(35). When the lower-GI weight-loss diet
was compared with a conventional weight-
loss diet (36), both groups lowered A1C
significantly with no significant differences
between groups. The lower-GI diet re-
duced A1C significantly less than the
very-low-carbohydrate diet (16).
A study in youth with type 1 diabetes
(37) found that individuals advised to
follow a lower-GIdiet had significant reduc-
tions in A1C compared with individuals
advised to follow a carbohydrate-exchange
diet, despite the fact that the mean GI for
the two diet groups was not significantly
different. Two studies indicated that educa-
tion can change food selection and may
(38) ormaynot (39) affect theGIof the diet.
Three meta-analyses (40–42) evalu-
ated GI. Anderson et al. (41) included
no studies meeting this review’s criteria;
Brand-Miller et al. (40) included one (37);
and Thomas and Elliott (42) included
three (32,33,37). These three studies
from the meta-analyses are included
above (32,33,37).
CVD risk. Mixed results were found for
the five RCTs comparing low-GI with
high-GI diets for lipoprotein measures.
Two studies found a significant reduction
in total cholesterol (31,32) with one of the
two reporting a significant reduction in
LDL cholesterol and apolipoprotein
(apoB) (32) for the lower-GI diet. The
other three studies found no significant
changes between groups (19,33,34).
Results were mixed in studies compar-
ing lowerGIwith other dietary approaches.
Significantly increased HDL cholesterol
was found with lower GI versus higher-
cereal fiber but no significant differences in
other measured CVD risk markers (35).
Total cholesterol was significantly lowered
with both a lower-GI diet and a traditional
diet without significant differences be-
tween groups; however, LDL cholesterol
was significantly higher with the lower-GI
diet versus the traditional diet (36). A very-
low-carbohydrate diet reduced TGs sig-
nificantly and increased HDL cholesterol
significantly compared with a lower-GI,
reduced-calorie diet, with no significant
differences in total cholesterol and LDL
cholesterol (16).
A cross-sectional study (43) of men
with type 2 diabetes described a statisti-
cally significant trend toward decreasing
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adiponectin with increasing quintiles of
GI.
Summary of GI research since 2002
In general, there is little difference in
glycemic control and CVD risk factors
between low-GI and high-GI or other
diets. A slight improvement in glycemia
may result from a lower-GI diet; however,
confounding by higher fiber (16,33,35)
must be accounted for in some of these
studies. Furthermore, standardized defi-
nitions of low GI need to be developed
and low retention rates on lower-GI diets
must be addressed (16,33,35).
Dietary fiber
The Institute of Medicine defines dietary
fiber as consisting of nondigestible (not
digested in the human small intestine)
carbohydrates and lignin that are intrinsic
and intact in plants (44). Quantification
of the dietary fiber in research studies may
be on the basis of dietary recommenda-
tions, grams per 1,000 kcals, the amount
added, or its distribution within the study
population. Functional fibers are beyond
the scope of this systematic review, and
thus functional fiber and total fiber were
not included in this review.
Glycemic control. Seven RCTs exam-
ined the effects of moderate amounts of
fiber supplements (4–19 g/day) on glyce-
mic control in adults with type 2 diabetes
(45–51). Durations of follow-up ranged
from 4 to 12 weeks, and sample sizes
were small (12–60 participants in the fi-
ber intervention). All studies were random-
ized; all studies analyzed participants
according to treatment assignment; com-
pletion of follow-up was .80% for two
of the studies (46,51); two of the studies
blinded participants to diet treatment
(48,51); and two were double-blinded
(45,46). In general, these studies support
the idea that fiber supplements may im-
prove postprandial glycemia; however, lit-
tle improvement in A1C was observed.
Two dietary counseling RCTs exam-
ined the effects of dietary fiber as part of
an intervention diet. In the first study,
individuals on the low-GI diet showed
small but significant improvements in
A1C (after controlling for weight loss, fiber,
or carbohydrate) and FBG at 6 months
compared with those on the high–cereal fi-
ber diet (35). In the second study, individ-
uals on a moderate-carbohydrate (51%),
high-fiber (27 g/1,000 kcals), lower-GI,
moderate-fat diet had significant decreases
in postprandial glucose variability after 4
weeks comparedwith a lower-carbohydrate
(44%), lower-fiber (8 g/1,000 kcal), higher-
GI, higher-MUFA diet (52).
Markers of improved insulin sensitivity
(adiponectin) or inflammation (C-reactive
protein [CRP], tumor necrosis factor-R2
[TNF-R2]) were assessed in three cross-
sectional reports (43,53,54). Higher cereal
or fruit fiber intakes were associated with
higher levels of adiponectin (43,53,54) and
lower levels of CRP (53,54) or TNF-R2
(53,54). Another cross-sectional study
(55), using a 3-day weighed diet, found
that individuals with type 2 diabetes and
the metabolic syndrome had significantly
lower intakes of total dietary fiber (specifi-
cally whole grains and fruits) than those
with diabetes but without the metabolic
syndrome; however, there were no associ-
ations between fiber intake and A1C or
FBG in either group.
The time period of the meta-analysis
by Anderson et al. (41) is before any of the
articles in this systematic review were
published, therefore the meta-analysis re-
sults are not included here.
CVD risk. All RCTs described above
assessed lipoproteins (35,45–52). Four
studies found no significant difference
between intervention and control groups
for thesemeasures (46,48–50). One study
found that psyllium (vs. cellulose) sup-
plements (45) significantly improved
HDL cholesterol; a second study found
that a higher-fiber, lower-fat, and lower-
GI diet versus a lower-fiber, higher-fat diet
produced significantly lower total choles-
terol, LDL cholesterol, andHDL cholesterol
(52). In addition, one cross-sectional study
found that a diet higher in soluble fiber
from whole grains was associated with a
lower TG level (55). In contrast, Jenkins
et al. (35) found that the lower-GI, high–
cereal fiber diet increased HDL cholesterol
significantly versus the higher-GI diet, and
Ble-Castillo (51) found that native banana
starch increased TGs, whereas soy milk de-
creased TGs.
The Nurses’ Health Study (NHS)
found lower CVD-specific mortality in
women with diabetes associated with
bran intake after adjustments for lifestyle
and dietary factors (56).
Summary of fiber research
since 2002
The majority of the reviewed evidence
indicates that adding fiber supplements in
moderate amounts (4–19 g) to a daily diet
leads to little improvement in glycemia
and CVD risk markers.
Fat amount
Glycemic management
Eight clinical trials examined low-fat eat-
ing patterns (21–23,29,57–60). One trial
studied adults with type 1 diabetes (29),
whereas the rest studied adults with type
2 diabetes; duration of follow-up ranged
from 3 days to 74 weeks, and sample sizes
of participants completing follow-up
ranged from 10 to 48 participants per
study group. All eight trials were outpa-
tient nutrition counseling interventions:
one single-arm (57), two crossover RCTs
(22,29), and five parallel RCTs. Four trials
reduced total fat intake to ,25% of daily
energy intake (21–23,57), and for the
rest, fat intake was 25–30%. All studies
analyzed participants according to treat-
ment assignment, and completion of
follow-up was $80% except in three
studies (29,59,60).
A1C decreased with a low-fat diet
in one of seven studies in which it was
measured (58). In that study (58), in-
tensive dietary advice for a lower-fat,
moderate-carbohydrate, higher-fiber
diet in adults with poor glycemic control
significantly decreased A1C compared
with the control group. Insulin sensitiv-
ity by euglycemic-hyperinsulinemic
clamp improved in the lower-fat diet
compared with the conventional diet in
one study (29).
Two weight-loss RCTs by the same
group compared meal replacements ver-
sus conventional diets (59,60) and
found significant reductions in FBG
over short durations with meal replace-
ments. One study carried out for 12
months showed no persistent difference
in FBG between groups, although signif-
icantly more subjects in the meal re-
placement group had reductions in
diabetic medications (60).
In addition to the information from
the clinical trials, a cross-sectional study
(61) found that higher-fat intake corre-
lated with significantly higher A1C.
CVD risk
Of the seven studies that measured CVD
risk factors, only one had significant find-
ings. In a small single-arm study (57)
comparing 3 days on a low-fat, fiber-rich
diet with study participants’ baseline
higher-fat diet, both total cholesterol
and HDL cholesterol decreased signifi-
cantly.
The cross-sectional study (61) found
that higher-fat intake correlated with
higher levels of total cholesterol and
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LDL cholesterol as well as coronary artery
calcium.
Summary of low-fat research since
2002
Lowering total fat intake infrequently
improved glycemic control or CVD risk
factors in clinical trials involving individ-
uals with diabetes. Lowering fat intake in
individuals with diabetes may improve
total cholesterol and LDL cholesterol but
may also lower HDL cholesterol.
Fat typedFor this review, the type of
fat refers to the proportion of total energy
from a specific fatty acid or fatty acid
category. Categorization may be on the
basis of the number of, the location of, or
the configuration of double bonds. Satu-
rated fatty acids (SFAs) may be assessed
based on distribution within the study
population or recommended dietary levels.
Omega-3 fatty acids are usually evaluated
as milligrams per day or as a distribution
within the population rather than on the
basis of percent of energy intake.
Saturated fatty acids
Glycemic control. One RCT in individ-
uals with type 2 diabetes compared gly-
cemic control outcomes for SFAs versus
MUFAs with the total fat remaining equal
(62) and did not find a significant differ-
ence between diets for postprandial glu-
cose or insulin response.
CVD risk. A 3-week study (62) reported
no improvement in postprandial lipid tol-
erance except for a small but significant
reduction in small VLDL TGs when sub-
jects consumed a low SFA diet (8% kcal
compared with 17% as SFA).
Summary of SFAs research since 2002
The results from the one study relevant to
this topic indicate that the type/amount of
fatty acid does not affect postprandial
glycemic control so long as the amount
of total fat is equivalent. An intriguing
idea for future research is that lowering
SFA or increasing MUFA may increase
glucagon-like peptide-1 activity, thereby
reducing postprandial TG.
Omega-3 fatty acids
Glycemic control. Three blinded RCTs
in individuals with type 2 diabetes (63–
65) found that omega-3 fatty acid supple-
ments may increase FBG by a small but
significant amount. However, a fourth
blinded RCT (66) observed a significant
decrease in A1C with supplementation
compared with controls. In the meta-
analysis by Hartweg et al. (67), six studies
met this systematic review criterion
(63–65,68–70) and are included in this
section.
CVD risk. Three RCTs using omega-3
fatty acid supplements (4 g/day eicosa-
pentaenoic acid [EPA] or docosahexae-
noic acid [DHA]) (64), 2.6 g/day EPA plus
DHA (65), or 4 g/day fish oil (68) versus
controls of corn or olive oil observed an
increase in HDL cholesterol, particularly
the HDL-2 and HDL-2b fractions. One of
these studies (64) also found a decrease in
the HDL-3 fraction with EPA supplemen-
tation. Most studies (64,65,68–70) ob-
served significant decreases in TGs with
EPA, fish oil, or EPA/DHA combination;
however, one (64) showed an increase in
TGs with supplementation of DHA alone.
A one-armed clinical trial (71) also
found a significant increase in HDL cho-
lesterol and a significant decrease in TGs
with an EPA/DHA combination.
One study (73) focused on whole-
food omega-3 intake in a prospective co-
hort and found that baseline marine
omega-3 fatty acid intake was inversely
associated with TG.
Summary of omega-3 fatty acids
research since 2002
Overall it appears that supplementation
with omega-3 fatty acids does not improve
glycemic control but may have beneficial
effects on CVD risk biomarkers among
individuals with type 2 diabetes by reduc-
ing TGs (in some but not all studies). Other
benefits (e.g., increasing HDL cholesterol
or decreasing LDL cholesterol) are not
clearly defined.
ProteindThis section reviews studies
examining the effects of varying the amount
of daily protein intake or the source of
protein intake and further distinguishes
those studies that included individuals
with diabetic kidney disease (DKD).
Amount of protein, individuals
without DKD
One metabolic unit-type crossover RCT
(25) and two parallel dietary consultation
RCTs (23,74) examined the effects of
higher protein versus usual protein intake
(30% vs. 15% of calories as protein with
fat remaining constant at 25–30%) on gly-
cemic control and CVD risk in individuals
with type 2 diabetes. Durations of follow-
up ranged from 4 to 16weeks, and sample
sizes were small (range 12–29 partici-
pants in the higher-protein intervention).
All studies analyzed participants accord-
ing to treatment assignment, completion
of follow-up was .80%, and no studies
were blinded.
A 5-week weight-maintenance study
(25) observed a significant reduction in
A1C and 24-h glucose response and sig-
nificantly lower fasting TGs on the
higher- versus lower-protein eating pat-
terns. A study of 8 weeks of weight loss
followed by 4 weeks of weight mainte-
nance (74) found no significant differences
between higher- and lower-protein groups
for A1C; however, significant decreases
in serum total cholesterol and LDL cho-
lesterol were observed on the higher-
versus lower-protein diets. Another
study (23) and a 1-year follow-up of
the Parker and colleagues study (24) re-
ported no significant differences be-
tween groups in glycemic control or CVD
risk factors.
Amount of protein, individuals
with DKD
Four parallel RCTs examined the effects
of lower versus usual protein intake on
glycemic control, CVD risk factors, and
renal function markers in individuals
with types 1 and 2 diabetes and micro-
albuminuria (75), macroalbuminuria
(76,77), or both (78). Durations of follow-
up ranged from 1 to 4 years, sample
sizes were small (23–47 participants in
the intervention groups), and retention
rates were .80% in two studies (76,77).
One study blinded physicians to diet
treatment (75). Two studies achieved
lower protein intakes of 0.86–0.89 g
protein/kg/day versus usual protein in-
takes (1.02–1.24) (76,77), whereas in the
other two studies, the lower-protein
group had higher actual protein intakes
versus the control groups (75,78). None
of the studies found significant differences
between groups for glycemia, CVD risk
factors, or renal function (glomerular
filtration rate [GFR], various measures
of proteinuria). At the levels of protein
achieved, no reduction in serum albumin
was noted.
Two meta-analyses addressed protein
restriction in people with diabetes and
micro- and macroalbuminuria. The meta-
analysis by Pan et al. (79) included four
studies meeting this review ’s criteria
(75–78), and the Cochrane analysis by
Robertson et al. (80) included three studies
(75–77). These four studies (75–78) are in-
cluded above.
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Source of protein, individuals with
DKD
Four RCTs examined the effects of source
of protein intake on glycemic control, CVD
risk factors, and renal function in indi-
viduals with type 2 diabetes and micro-
albuminuria (81) or macroalbuminuria
(82–84). Durations of follow-up ranged
from 4 weeks to 4 years, and sample sizes
were small (14–20 participants in the des-
ignated source interventions). Two studies
had completion rates of.80% (81,83).
The nutrition source focus for twoRCTs
was soy. HDL cholesterol increased signif-
icantly and urinary albumin-to-creatinine
ratio decreased significantly with soy pow-
der versus casein powder supplementation
(82). The 4-year RCT reported that the re-
placement of 35% of animal protein with
textured soy protein resulted in significant
improvements in FBG and total choles-
terol, LDL cholesterol, and TGs, but no sig-
nificant changes in kidney function versus
control (83). In two crossover RCTs from
the same author group (81,84), the dark
chickenmeat group significantly improved
total cholesterol, TGs, and urinary albu-
min excretion rate, and the low-protein/
vegetables group significantly improved
total cholesterol and GFR versus the red
meat control group.
Summary of amount and source of
protein research since 2002
For individuals without DKD, higher pro-
tein eating patterns (30% of calories) may or
may not improve A1C; however, they ap-
pear to improve one or more CVD risk
measures.
For individuals with DKD and either
micro- or macroalbuminuria, reducing the
amount of protein from normal levels does
not appear to alter glycemic measures, CVD
risk measures, or the course of GFR. For in-
dividuals withDKD andmacroalbuminuria,
changing the source of protein to be more
soy based may improve CVD risk measures
but does not appear to alter proteinuria.
Question 2A: How do
macronutrients combine in
food groups to affect
glycemic response and CVD
risk reduction in people
with diabetes?
Nuts
The high MUFA content of most tree nuts
and peanuts and high PUFA content of
walnuts and pine nuts lends support to
the investigation of potential effects of
nuts on glycemic control and CVD risk in
individuals with diabetes. Since 2002,
three RCTs and two reports from the
NHS have been published on this topic
(30,85–89). All studies analyzed partici-
pants according to treatment assignment,
and two studies blinded participants to
treatment. Completion of follow-up was
greater than 85% for all studies, and two
of the three studies controlled for weight
change.
Glycemic control. Two RCTs (85–87)
tested the effects of walnuts against gen-
eral advice or advice to consume specific
PUFA-rich foods. There were no signifi-
cant differences among groups for glyce-
mic control. One double-blinded study
compared 10% of total calories from fat
of almonds or olive/canola oil in the con-
text of either a high-fat (37%) or low-fat
(25%) diet and also did not find signifi-
cant differences in glycemic control
(30).
CVD risk. Results relating to measures of
CVD risk were mixed. Addition of wal-
nuts led to no significant differences in
total cholesterol and LDL cholesterol;
however, improved endothelial function
was observed (85). In another study (86),
the walnut group achieved significant re-
ductions in LDL cholesterol and increases
in HDL cholesterol and the ratio of HDL-
to-total cholesterol relative to the other
treatment groups. However, a third study
(30) found that HDL cholesterol was sig-
nificantly lower in the group receiving al-
monds (vs. olive/canola oil). These
authors concluded that total dietary fat
had a greater effect on serum lipids than
did fat source (30).
Two cross-sectional studies reported
associations between nut consumption
and lower-risk CVD risk markers. Nuts,
as a part of the Mediterranean-style eating
pattern, had an independent effect on
adiponectin levels, which were 12%
higher in the highest nut intake quintile
versus the lowest (88). Consumption of
at least five servings per week of nuts or
peanut butter was significantly associated
with a more favorable lipid profile (lower
total cholesterol, LDL cholesterol, and
apoB-100). There were no significant as-
sociations for inflammatory markers
(89).
Summary of nuts research since 2002
Nut-enriched diets do not alter glycemia
in individuals with diabetes. The evidence
is mixed as to whether they have benefi-
cial effects on serum lipoproteins.
Whole grainsdThe 2010 “Dietary
Guidelines for Americans” (90) defines
whole grains as foods containing the en-
tire grain seed (kernel, bran, germ, and
endosperm).
Two single-blinded crossover RCTs
compared whole grains to fiber (47,48) in
individuals with type 2 diabetes. Duration
of follow-up was 5–12 weeks, sample
sizes were small (15–20 adults), and re-
tention rates were 74% or not reported
(47). Whole-wheat flour products did
not change glycemic measures over 5
weeks, while adding fiber (arabinoxylan)
to whole-wheat flour products resulted in
significantly lower postprandial glucose,
insulin, and fructosamine (47). In the sec-
ond RCT, A1C and FBG were not altered
significantly over 12 weeks with Salba (a
novel whole grain) or wheat bran (48).
Neither study found significant differen-
ces in CVD risk markers.
Two cross-sectional analyses from the
NHS found that higher intake of whole
grains was associated with lower levels of
markers of inflammation (CRP and TNF-
R2) (54) and with higher adiponectin
concentrations (88). One of the RCTs
also found CRP was significantly lower
in the whole grain versus the wheat bran
groups (48).
Summary of whole-grains research
since 2002
Whole-grain consumption does not appear
to be associated with improved glycemic
control in individuals with diabetes. How-




Two crossover and four parallel RCTs
(50,60,91–95) investigated the effects of
soy-based supplements on individuals
with type 2 diabetes. One of the above
RCTs reported glycemic andCVD informa-
tion in separate publications (91,92). Du-
rations of follow-up ranged from 6 weeks
to 1 year, retention rates were .80% for
four (91–95) of the six studies, sample sizes
were small (15–38 in the intervention
group), and four of the studies were double-
blinded (91–95). Five of the six studies
found no significant difference in glycemic
measures between groups (92,93) (50,94)
(60); however, two studies observed im-
provements in LDL cholesterol (91,93) or
total cholesterol (93) versus control. A
diet-counseling, randomized crossover
trial (52) found that legumes as part of
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a moderately high–carbohydrate, high-
fiber, and lower-GI diet improved post-
prandial glucose and CVD risk factors
compared with a higher-MUFA diet.
Isolated soy proteins that included
isoflavones
Three crossover RCTs compared soy pro-
tein for effects on glycemic and CVD risk
markers in postmenopausal women
with type 2 diabetes (96–98). Duration
of follow-up ranged from 4 to 12 weeks,
sample sizes were small (16–32), and all
studies were double-blinded. Two studies
found no significant differences between
groups in glycemic control measures or
lipoproteins (97,98), and one of these
found no difference in CRP or HOMA-
insulin resistance (IR) (97). However,
the third (96) showed significant reduc-
tions in A1C, fasting insulin, HOMA-IR,
total cholesterol, and LDL cholesterol in
the soy group compared with the control
group.
Summary of legumes research
since 2002
While the soy-derived supplements in the
studies were quite different, most studies
did not indicate a significant reduction in
glycemic measures or CVD risk factors
compared with controls.
Vegetables and fruitdOne
small short-term RCT addressed vegeta-
ble supplements in individuals with type
2 diabetes. At four weeks, garlic powder
tablets significantly improved FBG, fruc-
tosamine, and TGs (99). Higher-fiber
vegetables as part of a moderately high–
carbohydrate, high-fiber, and lower-GI
diet improved postprandial glucose and
CVD risk factors compared with a
higher-MUFA diet (52). In women with
type 2 diabetes, vegetables and fruit (as a
component of the Mediterranean-style
eating pattern score) were not associated
with adiponectin concentrations (88).
Summary of vegetable and fruit
research since 2002
Eating pattern research has not directly
addressed the role of vegetables and fruits
in people with diabetes. Of the few studies
found since 2002, results are mixed.
DairydFive RCTs (two crossover and
three parallel feeding trials) examined the
effects of dairy supplements on glycemic
control and CVD risk factors (one RCT
reported glycemic and CVD information
in separate publications) (91,92). Three
studies included adultswith type2 diabetes
and one included youths with type 1 dia-
betes (100). Duration of follow-up ranged
from 6 to 52 weeks, and sample sizes
ranged from 11 to 59 participants per
study group. All studies were randomized,
analyzed participants according to treat-
ment assignment, completion of follow-up
was.80%, and three were double-blinded
(91–94).
One RCT (100) found that adding
camel’s milk to the usual diets of youth
newly diagnosed with type 1 diabetes sig-
nificantly reduced A1C and mean dose of
insulin compared with usual diets alone.
Three RCTs comparing soy to dairy
(91–94) found no significant differences
between groups in glycemic control. How-
ever, two of the studies (91,93) did find
LDL cholesterol to be significantly higher
for the milk protein isolate (91) and casein
(93) groups (vs. the soy groups).
An ancillary report of a weight-loss
study (101) found that there was no re-
lationship between dairy calcium and gly-
cemic control or CVD risk markers.
Summary of dairy research since 2002
None of the components of dairy appear
to have an effect on glycemic control or
CVD risk reduction.
Meats, poultry, and fishdIn
two crossover RCTs from the same research
group (81,84), a usual diet with dark
chicken meat replacing red meat was com-
pared with a low-protein/vegetable diet.
Therewere no significant differences among
groups for FBG, LDL cholesterol, and HDL
cholesterol. Total cholesterol was signifi-
cantly lower after the chicken and the veg-
etable protein diet versus the red meat diet,
and TGs were significantly lower after the
chickendiet versus the redmeat diet and the
vegetable protein diet. In women with type
2 diabetes in theNHS (102), a high intake of
redmeat was significantly associated with fa-
tal coronary heart disease, coronary revascu-
larization, and total coronary heart disease. A
case-control study (103) indicated that a high
intake of fish protein was associated with a
decreased risk ofmicro/macroalbuminuria in
youth with type 1 diabetes.
Summary of meat research since 2002
Currently, there is limited evidence to
provide conclusive statements relating to
the intake of meat, poultry, and fish.
Overall summary of Question 2A
Research involving diabetes and food
groups is sparse and does not indicate
an advantage for specific foods in improv-
ing glycemic control. There is a possibility
that certain CVD risk factors could be
improved with the consumption of nuts
or whey.
Question 2B: How do
macronutrients combine in
eating patterns to affect
glycemic response and CVD
risk factors in people with
diabetes?dEating patterns included
but are not limited todlower carbohydrate,
lower fat, lower GI (see the respective sec-
tions in Question 1) as well as Mediterra-
nean and vegetarian.
Mediterranean-style eating pattern
AMediterranean-style eating pattern, based
on the reviewed studies, generally includes
more vegetables,whole grains, fruit, legumes,
nuts, fish, and MUFA/PUFA; less red meat
and SFAs; and some alcohol (wine) com-
pared with a traditional diet.
Summary of reviewed studies
Five RCTs (52,104–107) compared a
Mediterranean or modified Mediterranean-
style eating pattern to other eating pat-
terns over a period of 4 weeks to 4 years.
A4-year study (104) compared aweight-
reduction/maintenance Mediterranean-
style eating pattern to a lower-fat eating pat-
tern. Weight loss was similar, and there
were no significant differences in glycemic
control between groups. Adiponectin in-
creased similarly with both eating patterns.
De Natale et al. (52) found that a mod-
erately high–carbohydrate, high-fiber, and
lower-GI Mediterranean-style eating pat-
tern significantly improved postprandial
glucose compared with a higher-MUFA
Mediterranean-style eating pattern.
Three RCTs comparing Greek tradi-
tional or fast foods found no significant
differences between groups for glycemic
control and CVD risk factors (105–107).
A cross-sectional study (88) and a
case-control study (108) examined the
Mediterranean-style eating pattern to
address how adherence was related to
selected biomarkers. There were no sig-
nificant differences between adherence
tertiles for A1C (88,108), total cholesterol
(88,108), or LDL cholesterol (88). HDL
cholesterol was significantly higher and
TG was significantly lower in the highest
tertile of adherence to the Mediterranean-
style eating pattern (88); the highest ter-
tile of adherence also was associated
with a 56% reduction in risk of peripheral
arterial disease (108). The NHS (88)
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found that adherence to the Mediterranean-
style eating pattern was associated with
higher plasma adiponectin concentrations
in women with diabetes, and this was at-
tributed mainly to the intake of alcohol,
nuts, and whole grains.
An RCT (109) compared 4 oz. of red
wine daily to no alcohol. Fasting insulin
and HOMA decreased in both groups,
with the wine group having a signifi-
cantly greater decrease. Both groups sig-
nificantly reduced total cholesterol and
LDL cholesterol with no change in TG.
HDL cholesterol was significantly in-
creased in the wine group only, whereas
markers of inflammation (TNF, CRP, and
others) were significantly increased in the
control group.
Summary of Mediterranean-style eating
pattern research since 2002
There appears to be no advantage in using
the Mediterranean-style eating pattern
compared with other eating patterns for
glycemic control. There are mixed results
for CVD risk factors with some studies
indicating that the Mediterranean-style
eating pattern might improve HDL cho-
lesterol and TG. Individual components
of the Mediterranean-style eating pattern
(wine, high MUFA/olive oil) do not ap-
pear to have independent effects on gly-
cemic control, but may be responsible for
improvement in HDL cholesterol.
Vegetarian eating
patterndOne RCT (21,110) com-
paring a low-fat vegan eating pattern
and a conventional eating pattern found
that weight and A1C decreased in both
groups, with no significant difference be-
tween groups in the primary analyses. In
an ancillary analysis that removed partic-
ipants who did not complete follow-up
or who had medications changed dur-
ing follow-up, there was a significantly
greater decrease in A1C and LDL choles-
terol in the vegan group. In a 4-week
crossover RCT in individuals with early
DKD, a lacto-vegetarian eating pattern
did not show significant differences in
FBG, HDL cholesterol, or LDL cholesterol;
however, total cholesterol significantly de-
creased compared with the usual eating
pattern, and GFR significantly decreased
compared with both the usual and chicken
diets (81,84).
Summary of vegetarian eating
pattern research since 2002
Research is limited regarding vegetarian
eating patterns. Because of methodological
problems, more research is needed before
conclusive remarks can be made about the
associations between a vegetarian eating
pattern and glycemic control and CVD risk
factors.
Overall summary of Question 2B
Studies examining how eating patterns
are related to glycemic control and CVD
risk markers have varied with respect to
macronutrient distribution used to char-
acterize low-fat, Mediterranean, low-GI,
vegetarian, and lower-carbohydrate eat-
ing patterns. While some research sug-
gests that these eating patterns improve
glycemic and cardiovascular outcomes,
variability in research methods and defi-
nitions have complicated interpretation
of findings. Issues that could affect con-
clusions include retention rates, dietary
intervention and assessment methodol-
ogy, and data analysis approaches.




reduction in people with
diabetes?dVariability in study
methodology, including measurement of
dietary intake, retention rates, and con-
founding by weight loss, limits compar-
isons as to how macronutrient distribution
independent of weight loss affects out-
comes of interest. Although in many
instances there were not statistically sig-
nificant differences between dietary ap-
proaches, improvements were often seen
from baseline to follow-up in both in-
tervention groups supporting the idea
that several different macronutrient dis-
tributions may lead to improvements in
glycemic and/or CVD risk factors (Sup-
plementary Table 1).
Question 4: What should
guide the future directions
of research?dTheevidencepresented
in this review suggests that many different
approaches to MNT and eating patterns
are effective for the target outcomes of
improved glycemic control and reduced
CVD risk among individuals with dia-
betes. However, several gaps in the litera-
ture remain that warrant mentioning
here.
Most of the studies in the present
review examined the relationship of
macronutrients and foods to biochemi-
cal markers of glycemic control and CVD
risk. While research has long explored the
mechanisms underlying the relationship
between nutrition and glycemia, studies
have only just begun examining how nu-
trition relates to the endocrine functions of
fat tissue and other cardiovascular param-
eters. For example, future studies should
address:
c The role of adiponectin, which may be
responsive to changes in eating pat-
terns and has been associated with
better diabetes-relatedhealth outcomes in
epidemiological studies
c The relationship between fiber/whole-
grain intake and improved insulin sensi-
tivity and markers of inflammation (e.g.,
CRP and TNF)
c The role of omega-3 fatty acids in relation
to adipose tissue inflammation, throm-
bosis, and lipidmetabolism in the context
of observations that higher intakes are
associated with reduced CVD mortality,
particularly sudden cardiac death
c The impact of very-low-carbohydrate
and moderately low–carbohydrate eating
patterns on long-term complications
such as nephropathy
c The impact of postprandial excursions
and hyperglycemia on inflammatory
response and subsequent CVD risk
In addition to these biochemical
mechanisms underlying nutrition-related
CVD risk, the interplay between specific
nutrients and dietary macronutrient com-
position has yet to be thoroughly evalu-
ated. The use of technology such as
continuous glucose monitors to evaluate
the impact of macronutrients in isolation,
in the presence of specific nutrients, in
the context of a mixed meal, and in overall
eating patterns must be elucidated in order
to fully understand how diet impacts gly-
cemic control.
Moving forward, it is essential to con-
sider that individuals benefit differently
from various nutritional approaches. Stud-
ies on gene-diet interactions and the impact
of various macronutrient compositions
across the continuum of dysglycemia/
insulin resistance warrant additional inves-
tigation. Related to this tailored approach
to MNT, it should be noted that individual
adherence to nutrition recommendations is
highly variabledand generally suboptimal.
Research is needed to develop strategies
that enhance adherence and to determine
if certain nutritional approaches promote
greater adherence than others.
Continued support is needed for
large, multicenter trials with clinical event
end points. Diabetes care involves mon-
itoring risk factors for bothmacrovascular
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and microvascular complications and
therefore the sample size needed to detect
multiple biologically and clinically rele-
vant effect sizes requires special consid-
eration. Furthermore, the duration of
follow-up needs to be adequate relative
to the outcomes of interest, and strategies
should be used to improve retention.
When dropout and/or missing data are
extensive, special analytic strategies may be
necessary to reduce the potential for selec-
tion bias. Study design and statistical anal-
yses should consider time-varying factors,
such as changes inweight andmedications,
which may independently impact study
outcomes, especially in small-scale efficacy
trials. Finally, due to the large volume
and variety of research regarding diet and
diabetes-related health outcomes, rigorous
systematic reviews and meta-analyses need
to be conducted so that researchers, clini-
cians, patients, and funding agencies are
aware of the most recent research and the
direction in which it is heading.
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